Orthofix Medical (OFIX) to Release Quarterly Earnings on Tuesday

Orthofix Medical (NASDAQ:OFIX) is projected to release its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Orthofix Medical to post earnings of $0.44 per share and revenue of $218.7150 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Orthofix Medical Price Performance

Shares of NASDAQ OFIX opened at $13.38 on Tuesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.47 and a quick ratio of 1.38. The company has a market cap of $529.85 million, a price-to-earnings ratio of -4.42 and a beta of 0.78. The stock’s 50-day moving average is $14.47 and its two-hundred day moving average is $14.65. Orthofix Medical has a 1-year low of $10.24 and a 1-year high of $20.48.

Insider Activity at Orthofix Medical

In other news, CFO Julie Andrews sold 4,873 shares of Orthofix Medical stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $14.38, for a total transaction of $70,073.74. Following the sale, the chief financial officer owned 58,039 shares in the company, valued at approximately $834,600.82. The trade was a 7.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Massimo Calafiore sold 9,797 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $15.21, for a total value of $149,012.37. Following the completion of the sale, the chief executive officer directly owned 217,237 shares of the company’s stock, valued at $3,304,174.77. The trade was a 4.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 24,270 shares of company stock valued at $370,958 in the last 90 days. Insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in OFIX. Kestra Advisory Services LLC acquired a new stake in shares of Orthofix Medical in the fourth quarter valued at approximately $56,000. Mackenzie Financial Corp purchased a new stake in Orthofix Medical in the 3rd quarter valued at $148,000. Strs Ohio acquired a new stake in Orthofix Medical during the 1st quarter worth $150,000. The Manufacturers Life Insurance Company boosted its stake in Orthofix Medical by 21.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 14,867 shares of the medical device company’s stock worth $166,000 after purchasing an additional 2,589 shares during the period. Finally, Creative Planning purchased a new position in Orthofix Medical during the 3rd quarter worth $172,000. Institutional investors and hedge funds own 89.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on OFIX shares. TD Cowen started coverage on shares of Orthofix Medical in a report on Tuesday, January 27th. They issued a “hold” rating and a $14.00 target price on the stock. Stifel Nicolaus began coverage on shares of Orthofix Medical in a research report on Tuesday, October 28th. They issued a “buy” rating and a $22.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Orthofix Medical in a research report on Thursday, January 22nd. Finally, Barrington Research boosted their target price on shares of Orthofix Medical from $17.00 to $18.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $20.00.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.